Topamax Appears to Impair Cognitive Function

In a study published in Neurology, Dr. M. C. Salinsky, of Oregon Health and Sciences University, and colleagues examined the cognitive effects of topiramate (Topamax) and gabapentin (Neurontin) versus a placebo:

Four of six measurements of cognition revealed significant differences between the gabapentin and topiramate groups, Salinsky's team reports, with the subjects given topiramate having poorer test performance than did the subjects given gabapentin after 12 weeks.

The risk of impaired cognitive function with topiramate "appears to be substantial and is at a level that could have significant adverse effects on daily and occupational functioning," the researchers note.

However, they also point out that lower doses than those used in the study may be effective for patients with epilepsy and might have a lower risk of cognitive impairment.

Source: ReutersHealth eLine